ARIXTRA 7.5 MG / 0.6 ML — DIN 02258056
FONDAPARINUX SODIUM : 7.5 MG / 0.6 ML · ASPEN PHARMACARE CANADA INC. · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ARIXTRA?
ARIXTRA 7.5 MG / 0.6 ML contains FONDAPARINUX SODIUM : 7.5 MG / 0.6 ML. It is listed in the Health Canada Drug Product Database under DIN 02258056, held by ASPEN PHARMACARE CANADA INC., supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 17-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ARIXTRA used for?
ARIXTRA® (fondaparinux sodium, injection) is indicated for: Prophylaxis of venous thromboembolic events (VTE) for up to one month post-surgery in patients undergoing orthopedic surgeries of the lower limbs such as hip fracture, knee surgery or hip replacement surgery. Prophylaxis of venous thromboembolic events (VTE) in patients undergoing abdominal surgery who are at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery. Treatment of Acute Deep Vein Thrombosis (DVT) and treatment of Acute Pulmonary Embolism (PE). Management of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) for the prevention of death and subsequent myocardial infarction. Management of ST segment elevation myocardial infarction (STEMI) for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who initially are to receive no form of reperfusion therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Fondaparinux cost around the world?
Fondaparinux is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 22 | USD███.██ |
| Italy | prezzo al pubblico (classe A) | 5 | 5 | EUR███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Iceland | max wholesale | 1 | 3 | ISK███.██ |
| Australia | ex-manufacturer | 1 | 1 | AUD███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
| Slovakia | categorised final price | 1 | 1 | EUR███.██ |
37 pack listings across 17 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Fondaparinux pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Fondaparinux in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Fondaparinux, across 8 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ASPEN PHARMACARE CANADA INC. | 4 | 2 | ARIXTRA | Sourceable in Canada |
| DR REDDY'S LABORATORIES LTD | 4 | 2 | FONDAPARINUX SODIUM INJECTION | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 7.5 MG / 0.6 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | Package of 10: 2.5 mg ARIXTRA® in pre-filled 0.5 mL single use syringe; 5 mg* ARIXTRA® in 0.4 mL single use pre-filled syringe; 7.5 mg ARIXTRA® in 0.6 mL single use pre-filled syringe; 10 mg* ARIXTRA® in 0.8 mL single use pre-filled syringe. |
| Storage | If ARIXTRA® is added to a 0.9% saline minibag it should be infused immediately, but can be stored between 15-30°C for up to 24 hours. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Fondaparinux |
|---|---|
| ATC code | B01AX05 |
| AHFS class | 20:12.04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02258056 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2258056 |
| Brand name | ARIXTRA |
| Generic / active ingredient | FONDAPARINUX SODIUM : 7.5 MG / 0.6 ML |
| Market authorization holder | ASPEN PHARMACARE CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | B01AX05 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AX |
| Current status | MARKETED |
| Status date | 17-Jul-2018 |
| Original market date | 2008-04-17 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ARIXTRA | 2.5 MG / 0.5 ML | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | 02245531 |
| FONDAPARINUX SODIUM INJECTION | 2.5 MG / 0.5 ML | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | 02406853 |
| FONDAPARINUX SODIUM INJECTION | 7.5 MG / 0.6 ML | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | 02406896 |
| ARIXTRA | 5 MG / 0.4 ML | SOLUTION | ASPEN PHARMACARE CANADA INC. | DORMANT | 02451700 |
| ARIXTRA | 10 MG / 0.8 ML | SOLUTION | ASPEN PHARMACARE CANADA INC. | DORMANT | 02451719 |
| FONDAPARINUX SODIUM INJECTION | 5 MG / 0.4 ML | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | 02406888 |
| FONDAPARINUX SODIUM INJECTION | 10 MG / 0.8 ML | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | 02406918 |
2 · Same class — other molecules in ATC B01AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fondaparinux | ARIXTRA · FONDAPARINUX SODIUM INJECTION | 8 | 4 | Yes |
| Defibrotide | DEFITELIO | 1 | 1 | Yes |
| Caplacizumab | CABLIVI | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AB | Antithrombin · Dalteparin · Danaparoid · Enoxaparin · Heparin · Heparin, Combinations · Nadroparin · Tinzaparin | 128 | 82 |
| B01AC | Abciximab · Acetylsalicylic Acid · Cangrelor · Clopidogrel · Combinations · Dipyridamole · Epoprostenol · Eptifibatide · Prasugrel · Selexipag · Ticagrelor · Ticlopidine · Tirofiban · Treprostinil · Vorapaxar | 158 | 66 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AE | Argatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin | 18 | 11 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · Streptokinase · Tenecteplase · Urokinase | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.